Precision Medicine for the Next Standard of Care
Triple Helix Science is a precision medicine company operating at the intersection of gene therapy, regenerative medicine, stem cell science, and longevity sciences
Triple Helix Science is a precision medicine company operating at the intersection of gene therapy, regenerative medicine, stem cell science, and longevity sciences
We combine trusted medical expertise with innovative solutions to give you care that's precise, personal, and always within reach.
Targeting cellular mechanisms and metabolic pathways to extend human vitality and delay age-related decline.
Optimizing mitochondrial efficiency, insulin sensitivity, and lipid homeostasis for systemic cellular energy.
Pioneering cellular rejuvenation and endocrine signaling to preserve and extend reproductive vitality.
Enhancing cellular autophagy, genomic stability, and telomere integrity to maximize active healthspan.
Harnessing stem cell biology and targeted gene therapeutics to repair and regenerate vital tissue architecture.
Combating toxic proteins and neuroinflammation to preserve cognitive function and halt neural decay.
Optimizing neuromuscular health, protein synthesis, and tissue repair to sustain lifelong physical performance.
Developing precision gene therapies and immunotherapies to target cellular aberrations and neutralize tumor progression.
Triple Helix Science is an institutional-grade biotechnology company built for governments, institutions, and enterprise partnerships. We are a precision medicine company delivering IP-protected therapeutics grounded in a science-first philosophy working at the intersection of gene therapy, regenerative medicine, stem cell science, and longevity sciences.
About
Founder & Chief Executive Officer
The genome is not a mystery to be solved — it is an instruction set to be read.
Our work is translation: from genetic sequence to clinical outcome, with the precision that institutional medicine demands.
Dr. Sewell brings senior clinical leadership in regenerative medicine and a track record of IP-protected research programme development, founding Triple Helix Science with a sovereign-partnership focus. Under his direct leadership,
THS achieved a defining clinical milestone: a Phase 1 trial demonstrating reversal of dementia progression.
Precision medicine as a public good, not a luxury. To develop and deliver gene and regenerative therapies that shift the global standard of care from reactive symptom management to predictive, genome-based intervention — available to nations and institutions, not only to individuals.
Genetic medicine as standard of care, not experimental fringe. A world where aging populations and chronic disease burdens are addressed through predictive, personalised medicine infrastructure built at the civilisational level, in partnership with sovereign health systems that THS is equipping today.
Partner with us to advance genomic precision medicine, longevity science, and transformative therapeutics.
At Triple Helix Science, our mission is to decode and combat the biological mechanisms of aging. We focus specifically on the intersection of three critical fields: Longevity, Neuroprotection, and Muscle Biology. By targeting cellular decay at its root, we aim to extend human healthspan—ensuring that added years of life are matched with sustained physical and cognitive vitality.
Aging is a systemic process where cellular decline in one organ accelerates deterioration across others. By simultaneously optimizing mitochondrial and telomeric health, clearing misfolded toxic proteins and reducing neuroinflammation in the CNS, and sustaining neuromuscular junction integrity, we create synergistic interventions that preserve full-body functional vitality.
Triple Helix Science operates on an institutional-grade translational model. We develop proprietary, IP-protected therapeutic protocols validated through rigorous clinical trials, including Phase 1 human studies demonstrating reversal of dementia progression. Through sovereign and enterprise partnerships, our therapies are deployed directly into clinical practice.
We collaborate with sovereign healthcare systems, research universities, sovereign wealth funds, and enterprise pharmaceutical organizations seeking IP-backed translational science in cellular longevity, regenerative medicine, and gene therapy.
Discover the science and mission behind our approach.
We are here to help you understand our process.
Send us a message to learn more about our research programs and partnerships.